CYLTEZO Pen 40 MG/0.4 ML Starter Pack - Psoriasis/Uveitis (4 count)

RxCUI: 2680757
RxNorm name: CYLTEZO Pen 40 MG/0.4 ML Starter Pack - Psoriasis/Uveitis (4 count)
Display name: CYLTEZO Pen 40 MG/0.4 ML Starter Pack - Psoriasis/Uveitis (4 count)
Full name: CYLTEZO Pen 40 MG/0.4 ML Starter Pack - Psoriasis/Uveitis (4 count)
Term type: PSN
Status: DailyMed mapping
Updated: 2026-06-04 23:38:47

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761058	Cyltezo	adalimumab-adbm	351(k) Interchangeable	Rx	2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Cyltezo	ADALIMUMAB-ADBM	Boehringer Ingelheim Pharmaceuticals, Inc.	115ea79b-7209-7f19-b35d-36ec0828fbf5	2026-05-22	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2680757

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
115ea79b-7209-7f19-b35d-36ec0828fbf5	CYLTEZO Pen 40 MG/0.4 ML Starter Pack - Psoriasis/Uveitis (4 count)	PSN	17	These highlights do not include all the information needed to use CYLTEZO safely and effectively. See full prescribing information for CYLTEZO. CYLTEZO ® (adalimumab-adbm) injection, for subcutaneous use Initial U.S. Approval: 2017 CYLTEZO (adalimumab-adbm) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betw	20260303
115ea79b-7209-7f19-b35d-36ec0828fbf5	{4 (0.4 ML adalimumab-adbm 100 MG/ML Auto-Injector [Cyltezo]) } Pack [Cyltezo Pen 40 MG/0.4 ML Starter Pack - Psoriasis]	BPCK	17	These highlights do not include all the information needed to use CYLTEZO safely and effectively. See full prescribing information for CYLTEZO. CYLTEZO ® (adalimumab-adbm) injection, for subcutaneous use Initial U.S. Approval: 2017 CYLTEZO (adalimumab-adbm) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betw	20260303
115ea79b-7209-7f19-b35d-36ec0828fbf5	Cyltezo Pen 40 MG/0.4 ML Starter Pack - Psoriasis/Uveitis (4 count)	SY	17	These highlights do not include all the information needed to use CYLTEZO safely and effectively. See full prescribing information for CYLTEZO. CYLTEZO ® (adalimumab-adbm) injection, for subcutaneous use Initial U.S. Approval: 2017 CYLTEZO (adalimumab-adbm) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betw	20260303